Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.
Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.
The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.
Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.
In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.
- Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
- Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
- Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.
Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.
Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for glaucoma, corneal disorders and retinal diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco. A live and archived webcast will be accessible through the Investors section of the Glaukos website.
Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology, has announced its participation in five major investor conferences in late 2024. The schedule includes appearances at the Stifel Healthcare Conference (Nov 19), Stephens Annual Investment Conference (Nov 20), BTIG Ophthalmology Day (Dec 2), Piper Sandler Annual Healthcare Conference (Dec 4), and Citi Global Healthcare Conference (Dec 5). Live and archived webcasts of these events will be accessible through the company's investor relations website.
Glaukos (NYSE: GKOS) reported strong Q3 2024 financial results with record net sales of $96.7 million, up 24% year-over-year. Glaucoma segment achieved record sales of $76.0 million (+30%), while Corneal Health sales reached $20.6 million (+5%). The company maintained a robust gross margin of 77% (82% non-GAAP) and raised its 2024 net sales guidance to $377-379 million. Despite revenue growth, Glaukos reported a net loss of $21.4 million ($0.39 per share), though improved from $30.4 million loss year-over-year. The company ended Q3 with approximately $267.2 million in cash and investments.
Glaukos (NYSE: GKOS) announced positive topline results from its Phase 3 confirmatory trial for Epioxa™, a next-generation corneal cross-linking therapy for keratoconus. The trial met its primary efficacy endpoint, demonstrating a clinically relevant and statistically significant improvement in maximum corneal curvature (Kmax) at 12 months. Key findings include:
1. A Kmax treatment effect of –1.0 diopter (p <0.0001)
2. 91.5% of treated patients completed the 12-month trial
3. No treatment-related serious adverse events reported
4. No evidence of systemic effects or changes in corneal endothelial cell counts
Glaukos plans to submit a New Drug Application (NDA) to the FDA by the end of 2024. If approved, Epioxa could become the first FDA-approved, non-invasive drug therapy for keratoconus that preserves the corneal epithelium.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, announced its participation in the American Academy of Ophthalmology (AAO) annual meeting from October 18-21, 2024, in Chicago. The company will showcase its technologies through scientific presentations and exhibit at booth #2608.
Glaukos is sponsoring an educational symposium titled 'iDose® TR: The Gateway to Interventional Glaucoma' on October 19, 2024. Key glaucoma posters will cover topics such as the effect of travoprost intracameral implant in eyes with prior failed selective laser trabeculoplasty, and long-term outcomes of trabecular micro-bypass stents with cataract surgery in POAG.
The event will also feature corneal health presentations, including a discussion on risk factors for complications after CXL for KCN. The AAO Annual Meeting is a significant gathering for ophthalmic professionals and industry executives.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, has announced plans to release its third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company will host a conference call and simultaneous webcast to discuss the results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Interested parties can access the live webcast through the company's investor relations website. To participate in the conference call, attendees should dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay of the call will be made available on the company's website following the event's conclusion.
Glaukos (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company, has announced its participation in two upcoming investor conferences. The company, which specializes in novel therapies for glaucoma, corneal disorders, and retinal diseases, will be present at:
1. The Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 12:45 p.m. ET in Boston, MA.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 12:20 p.m. ET in New York City, NY.
Glaukos has confirmed that live and archived webcasts of these events, where applicable, will be accessible through the Investors section of their official website at http://investors.glaukos.com.
Glaukos (NYSE: GKOS) reported strong financial results for Q2 2024, with record net sales of $95.7 million, up 19% year-over-year. The company's Glaucoma segment saw a 23% increase in net sales to $75.9 million, while Corneal Health net sales grew 7% to $19.8 million. Gross margin improved to 76%, with non-GAAP gross margin at 82%. Despite the revenue growth, Glaukos reported a net loss of $53.9 million, or ($1.06) per diluted share. The company raised its 2024 net sales guidance to $370-$376 million, up from the previous $357-$365 million range. Glaukos ended the quarter with approximately $266.4 million in cash and investments.
Glaukos (NYSE: GKOS), specializing in ophthalmic pharmaceuticals and medical technology, will release its second quarter 2024 financial results after market close on Wednesday, July 31, 2024. The announcement will be discussed by company management during a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET).
Access to the live webcast will be available on the company's investor relations website. Interested parties can join the conference call by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) with the Conference ID 7935742. A replay will be available on Glaukos' website after the call.
Glaukos (NYSE: GKOS) has entered into privately negotiated exchange agreements with certain holders of its 2.75% Convertible Senior Notes due 2027.
The company plans to repurchase $230 million in principal amount of these notes. The consideration will comprise shares of Glaukos' common stock and cash for fractional shares and accrued interest.
The exchanges are expected to close around June 25, 2024, and the shares issued will not be registered under the Securities Act of 1933.
This action is not an offer to sell or a solicitation to buy these securities in any jurisdiction where such actions would be illegal.
FAQ
What is the current stock price of Glaukos Corporation (GKOS)?
What is the market cap of Glaukos Corporation (GKOS)?
What is Glaukos Corporation?
What is the iStent Trabecular Micro-Bypass Stent?
When did Glaukos go public?
What is MIGS?
What is the iStent SA?
What recent achievements has Glaukos made?
What is the significance of Glaukos' products?
Who are Glaukos' partners?
What is Glaukos' mission?
How does Glaukos continue to innovate?
